|
Dermatological events in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy |
|||||||||
| Nature of event |
Events |
Time to event (months) |
Events during treatment |
Major events |
Histology |
DMARDsb |
Prednisoloneb |
Permanent withdrawal of anti-TNF-αc |
|
|
|
|||||||||
| No. (%) |
Mediana |
Range |
No. (%) |
No. (%) |
No. (%) |
No. (%) |
No. (%) |
No. (%) |
|
|
|
|||||||||
| Infection |
33 (25.8) |
9.1 |
1.1–61.1 |
24 (73) |
0 |
5 (15) |
20 (61) |
21 (64) |
4 (12) |
| Eczema |
20 (15.6) |
7.1 |
0.2–49.9 |
16 (80) |
1 (5) |
4 (20) |
8 (40) |
7 (35) |
3 (15) |
| Drug-related eruption |
15 (11.7) |
1.9 |
0.1–18.8 |
15 (100) |
1 (7) |
12 (80) |
6 (40) |
6 (40) |
7 47) |
| Ulcers |
9 (7.0) |
13.6 |
0.3–52.5 |
3 (33) |
1 (11) |
2 (22) |
7 (78) |
4 (44) |
1 (11) |
| Skin tumor, benign |
7 (5.5) |
12.9 |
2.0–18.1 |
7 (100) |
0 |
2 (29) |
5 (71) |
4 (57) |
0 |
| Skin tumor, malignant |
5 (3.9) |
4.5 |
1.1–38.0 |
4 (80) |
0 |
5 (100) |
2 (40) |
2 (40) |
1 (20) |
| Xerosis cutis |
6 (4.7) |
8.9 |
4.2–26.3 |
6 (100) |
0 |
1 (16) |
4 (67) |
1 (17) |
1 (17) |
| Vasculitis |
5 (3.9) |
12.0 |
1.5–49.9 |
4 (80) |
0 |
4 (80) |
3 (60) |
5 (100) |
1 (20) |
| Actinic keratosis |
5 (3.9) |
26.3 |
4.5–112.9 |
2 (40) |
0 |
3 (60) |
5 (100) |
2 (40) |
0 |
| CVI/varices |
4 (3.0) |
24.0 |
1.7–33.6 |
3 (75) |
0 |
0 |
3 (75) |
2 (50) |
0 |
| Psoriasis/psoriasiform |
3 (2.3) |
15.5 |
8.4–50.1 |
3 (100) |
0 |
3 (100) |
0 |
2 (67) |
1 (33) |
| Edema |
3 (2.2) |
8.2 |
4.0–39.6 |
2 (67) |
0 |
1 (33) |
1 (33) |
1 (33) |
0 |
| Stasis dermatitis |
3 (2.2) |
17.5 |
14.6–42.1 |
3 (100) |
0 |
1 (33) |
1 (33) |
1 (33) |
0 |
| Seborrheic dermatitis |
2 (1.5) |
0.4, 19.8 |
– |
2 (100) |
0 |
0 |
0 |
0 |
0 |
| Other event |
8 (6.0) |
5.0 |
1.9–25.9 |
6 (75) |
0 |
4 (50) |
4 (50) |
2 (25) |
2 (25) |
| Total |
128 (100) |
9.1 |
0.1–112.9 |
100 (78) |
3 (2) |
47 (37) |
69 (54) |
60 (47) |
21 (16) |
|
aMedian and range given for three cases or more; individual data given for two cases or fewer. bNumber of patients with concomitant DMARDs and prednisolone at the time of event. cPermanent discontinuation of TNF-α-blocking therapy because of the event. DMARD, disease-modifying anti-rheumatic drug; TNF, tumor necrosis factor. | |||||||||
Flendrie et al. Arthritis Research & Therapy 2005 7:R666 doi:10.1186/ar1724 |
|||||||||